All In Biotech

Drug Trial Radar · NCT06097663

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in an Adult Population With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Feb 15, 2024

Primary completion

Oct 27, 2024

Study completion Nov 4, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (variant allele frequency \[VAF\] ≥2%).

Conditions

  • Coronary Heart Disease
  • Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Interventions

  • MAS825Drug

    Active MAS825 single dose

  • MAS825 PlaceboDrug

    MAS825 placebo single dose

  • DFV890Drug

    Oral tablet of DFV890 active once daily

  • DFV890 placeboDrug

    Oral tablet of DFV890 placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
  2. Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
  3. Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression ModelTime frame: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Washington University

    St Louis, Missouri

  • Vanderbilt University Medical Cent

    Nashville, Tennessee

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.